Heart transplants with distant procurement after circulatory death ACE = angiotensin converting enzyme; AUC = area under the curve; BNP = brain natriuretic peptide; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; CV = cardiovascular; ED = emergency department; HF = heart failure; HF(P/R)EF = HF with (preserved/reduced) ejection fraction; HR = hazard ratio; MI = myocardial infarction; NYHA = New York Heart Association; OR = odds ratio; PAH = pulmonary arterial hypertension; RR = relative risk VE = ventilatory efficiency; QOL = quality of life; RCT = randomised controlled trial Patients with HF and a KCCQ (Kansas City Cardiomyopathy Questionnaire) overall summary score <60 (heavy symptom burden and impaired functional status and QOL) were randomised to a collaborative care patient-centred disease management intervention (n=187) or usual care (n=197) in the PCDM trial. Both trial arms had a significant 13.5-point improvement in the mean KCCQ overall summary score at 1 year (primary outcome) with no significant between-group difference (p=0.97), and this did not change when the effect over time was estimated using 3-, 6-and 12-month data (p=0.74). However, compared with usual care, the intervention was associated with a significantly lower 1-year mortality rate (4.3% vs. 9.6% [p=0.04]) and a greater improvement in the Patient Health Questionnaire 9 scores at 1 year among participants with depression (p=0.01), but the 1-year hospitalisation rates were similar (29.4% vs. 29.9% [p=0.87] ).
Comment:
The patient-centred disease management programme evaluated in this population-based cohort of HF patients failed to improve health status compared with usual care. The reported reduction in mortality was based upon small numbers of events, and should be regarded as hypothesis generating given that the study did not achieve its primary endpoint. This study highlights the difficulty in evaluating the efficacy of models of care in a clinical trial setting, and emphasises the need to focus HF disease management programmes on the highest risk patients (e.g. those with recent HF hospitalisation).
Reference: JAMA Intern Med 2015;175(5):725-32 Abstract
Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure Authors: Apostolo A et al. Summary: This retrospective study sought to assess whether an elevated intercept of ventilation on the VE (VE int ) indicated the presence of COPD in patients with HF. The researchers analysed the VE-VCO 2 relationship both as slope and intercept in 108 patients with HF, 106 with HF plus COPD and 95 with COPD, with 85 patients with PAH and 56 healthy subjects serving as positive and negative controls relative to VE-VCO 2 abnormalities, respectively. Slope and VE int varied in opposite directions across all groups (p<0.05), with VE-VCO 2 slope being greatest and lowest in the PAH control and healthy subjects, respectively, and no differences in slope values seen among patients with HF, HF plus COPD and COPD (32, 31 and 31, respectively). Compared with patients with HF only, PAH controls and healthy controls, those with HF plus COPD and COPD only had significantly higher VE int values (4.8 and 5.9 vs. 3.0, 2.3 and 3.9 L/min, respectively [p<0.01]). A VE int value of ≥4.07 L/min identified COPD or HF plus COPD with sensitivity of 71.6% and specificity of 72.0%.
Comment: Clinicians are often faced with determining whether dyspnoea is due to HF or COPD. The intercept of ventilation on the VE-VCO 2 relationship showed promise to allow identification of patients with COPD; however, there was substantial overlap. Future prospective studies in unselected populations will need to evaluate the diagnostic utility of ventilatory efficiency parameters to identify COPD in the presence or absence of HF, and whether these parameters change with longer term serial testing. † In patients with heart failure and left ventricular impairment within 3-14 days of acute myocardial infarction, in combination with standard therapy.
In post-MI heart failure protection comes as standard In this research, patients poorly adherent to evidence-based HF medication were randomised to an intervention group consisting of predischarge, nurse-led, self-management training, which focussed on identification of medication goals, facilitation of medication-symptom associations and use of a symptom response plan (n=44) or an attention control (usual care) group (n=42). Follow-up calls at 1 week (for both groups) did not include content on HF medications or symptoms for the attention control group. Compared with the attention control group, the intervention increased the likelihood of medication adherence (determined by nurse-assessed pill counts) across all timepoints assessed (3, 6 and 12 months; OR 3.92 [p=0.0007]).
Comment: Reminder systems and isolated educational strategies have limited efficacy in improving longer term adherence behaviour, especially in patients who are intentionally nonadherent. This study evaluated a nurse-delivered intervention to strengthen patients' beliefs regarding the need to take their medications. In a cohort of HF patients who had been identified as nonadherent, the intervention resulted in an almost 4-fold increase in medication adherence. This study again highlights the need to focus and tailor disease management interventions to those patients who are most likely to benefit, which in this instance involved identifying patients at high risk of nonadherence.
Reference: Am Heart J 2015;169(4):539-48 Abstract
Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics Authors: Cheng M-L et al. Summary: The diagnostic and prognostic values of metabolomics in HF were assessed in this research. Using data from 186 patients with HF and 51 healthy controls, a panel of metabolites identified by mass spectrometry, including histidine, phenylalanine, spermidine and phosphatidylcholine C34:4, was found to have similar diagnostic value to BNP level. The values in this panel had significantly improved at 6 and 12 months in an independent group of 32 patients with stage C HF who had recovered to NYHA functional class I at these timepoints. The combined endpoint of death or HF-related rehospitalisation was used for evaluation of prognostic values. A metabolite panel consisting of asymmetric methylarginine/arginine ratio, butyrylcarnitine, spermidine and the total amount of essential amino acids yielded significant prognostic values (p<0.0001) independent of BNP level and traditional risk factors. The metabolite panel had better prognostic value than BNP level (AUC 0.85 vs. 0.74) and Kaplan-Meier curves (log rank 17.5 vs. 9.95). The findings were corroborated in a validation cohort of 218 patients with stage C HF and 63 controls.
Comment: This interesting study demonstrated that a combination of a small number of metabolites provided comparable diagnostic accuracy and superior prognostic prediction to BNP level in selected samples of HF patients. Future studies will need to evaluate unselected patient cohorts and determine whether metabolomics could also be used to monitor disease severity in HF.
Reference : J Am Coll Cardiol 2015; 65(15):1509-20 Abstract Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death Authors: Dhital KK et al.
Summary:
These authors reported a case series of two men and one woman with medically refractive end-stage HF (transpulmonary gradient <8mm Hg and no previous cardiac surgery) who underwent transplantation at St Vincent's Hospital, Sydney, of Maastricht category III controlled hearts from donors after circulatory death. The donors were aged <40 years and the maximum warm ischaemic times were 22-28 min. Four hearts were retrieved through initial myocardial protection with a supplement care system for preservation, resuscitation and transportation; ex vivo organ care system perfusion times were 245-260 min. Arteriovenous lactate levels at the beginning and end of perfusion showed favourable lactate uptake. Temporary mechanical support was required for two of the patients. Normal cardiac function had been achieved within 1 week of transplantation in all three patients, with good recovery seen at the time of reporting (77-176 days post-transplantation).
Comment: Whilst orthotopic heart transplantation remains the gold-standard therapy for patients with refractory end-stage HF, donor shortage remains problematic with prolonged transplantation waiting lists. Organ donation after circulatory death (as opposed to organ donation after brain death) has been successfully applied in lung and abdominal organ transplantation. This important case series performed at St Vincent's Hospital in Sydney is the first report of successful heart transplantations from donors after circulatory death with the hearts procured at a distance requiring the use of an ex vivo cardiac perfusion device. This follows on from elegant preclinical work conducted by this group investigating how to increase the tolerance of hearts donated after circulatory death to ischaemia. The authors estimate that this will increase the potential donor pool by ~17%.
